Injectable Extended-Release Buprenorphine (XR-B) in a Correctional Setting: Qualitative Interviews

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06354465

Enrollment

Registered

2024-04-09

Start date

2023-07-01

Completion date

2024-07-01

Last updated

2024-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Criminal Justice, Opioid Use Disorder, Treatment Adherence and Compliance

Keywords

addiction, criminal justice, Medications for opioid use disorder

Brief summary

This qualitative study investigates the potential benefits and challenges of using a once-a-month injectable medication, known as extended-release buprenorphine (XR-B), to treat individuals with opioid use disorder (OUD) within a correctional setting. The research aims to understand if XR-B can be a feasible and effective alternative to the standard daily treatment and to identify which groups within the prison population may benefit the most from this treatment. In-depth interviews are conducted with incarcerated individuals and relevant stakeholders.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

Incarcerated individuals, inclusion criteria: * English speaking * Over the age of 18 * Diagnosed with opioid use disorder Incarcerated individuals,

Exclusion criteria

\- Diagnosed with Severe, Persistent, Mental Illness (SPMI) Rationale for Exclusion: These individuals suffer from severe mental health disease and therefore warrant greater protection, have greater risk for coercion, and offer insights to severe co-diagnosis treatment that, while important, remain outside the scope of general MAT implementation. Organizational Stakeholders, Inclusion Criteria: \- Employed or contracted by Rhode Island Department of Corrections (for organizational staff interviews) and involved with the Medication for Addiction Treatment (MAT) program Organizational Stakeholders,

Design outcomes

Primary

Measure	Time frame	Description
Qualitative Transcripts	1 year	A directed content analysis will identify key themes in structured interviews

Countries

United States

Contacts

Primary ContactJustin Berk, MD

justin_berk@brown.edu8064333960

Outcome results